Please login to the form below

Not currently logged in
Email:
Password:

GSK enters licensing deal for ARDS enzyme

Apeiron has granted GSK exclusive rights to its APN01 enzyme, in phase I development to treat Acute Respiratory Distress Syndrome

Apeiron Biologics has granted GlaxoSmithKline(GSK) exclusive rights to the Austrian company's APN01 enzyme, currently in phase I development to treat Acute Respiratory Distress Syndrome (ARDS).

The deal will see GSK pay Apeiron an up-front payment of £11m cash and equity investment. In addition, Apeiron will receive royalties on net sales. Should the enzyme go on to be launched for multiple indications, GSK would be liable for up to £207m in milestone payments.

Hans Loibner, CEO of Apeiron, said: "We are very pleased that we could attract GSK, one of the world's top pharmaceutical companies, to license this exciting project. I am convinced that Apeiron's know-how in this area, together with the extensive development and marketing capabilities of GSK, are the best way forward to bring an innovative therapy to patients worldwide."

Acute Respiratory Distress Syndrome (ARDS) is an acute, severe injury to the lungs associated with a variety of conditions, such as sepsis, aspiration of acidic gastric contents, trauma, postoperative complications, acute pancreatitis, and pneumonias eg due to infections with human influenza viruses. Currently, no effective drugs exist to treat ARDS, which has a mortality rate of 30 to 50 per cent.

3rd February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics